SCHEMBL1748556

SCHEMBL1748556

COc1cc(Cl)cc(C(C)Nc2cc(N3CCNCC3)ccc2S(C)(=O)=O)c1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 7/20 0.69
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ADRB1 P08588 3/20 0.42
HTR1A P08908 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
HTR3A P46098 1/20 0.39
HTR3D Q70Z44 1/20 0.39
HTR3C Q8WXA8 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
GUSB P08236 1/20 0.39
ALK Q9UM73 2/20 0.38
RIPK2 O43353 4/20 0.38
ACVR1 Q04771 4/20 0.38
NOD2 Q9HC29 4/20 0.38
CNR1 P21554 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748852 0.93 HTR6 (0.64) HTR6HPGDSMN1; SMN2ADRB1HTR1A
SCHEMBL1747990 0.91 HTR6 (0.68) HTR6HPGDSMN1; SMN2ADRB1HTR1A
Hydrochloric Acid SCHEMBL1748809 0.90 HTR6 (0.67) HTR6HPGDSMN1; SMN2ADRB1HTR1A
SCHEMBL12527143 0.87 HTR6 (0.64) HTR6HPGDSMN1; SMN2ADRB1HTR1A
SCHEMBL1747996 0.83 HTR6 (0.75) HTR6HPGDSMN1; SMN2GUSBALK
SCHEMBL1748316 0.81 HTR6 (1.00) HTR6HPGDSMN1; SMN2HTR1AALK
SCHEMBL27933437 0.81 HTR6 (0.47) HTR6HPGDSMN1; SMN2ADRB1HTR1A
SCHEMBL1748904 0.81 HTR6 (1.00) HTR6HPGDSMN1; SMN2HTR1AALK
SCHEMBL475397 0.81 HTR6 (1.00) HTR6HPGDSMN1; SMN2HTR1AALK
SCHEMBL475383 0.81 HTR6 (0.80) HTR6HPGDSMN1; SMN2HTR1AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968538-B2 Substituted arylamine compounds and methods of treatment GALENEA CORP. (US) 2011-06-28 US claimed
US-20120115850-A1 SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT BECKER OREN (IL) 2012-05-10 US disclosed
US-20120115850-A1 SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT BECKER OREN (IL) 2012-05-10 US disclosed
US-7968538-B2 Substituted arylamine compounds and methods of treatment GALENEA CORP. (US) 2011-06-28 US disclosed
US-7968538-B2 Substituted arylamine compounds and methods of treatment GALENEA CORP. (US) 2011-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115850-A1 SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT HTR6, HTR2A, HTR3B HTR6 1/4885HPGD 2326/4885SMN1; SMN2 3858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.